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DRUG EVALUATION
Opicapone for the treatment of Parkinson’s disease: an update
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aInterdisciplinary Excellence Centre, Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged,
Szeged, Hungary; bMTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences, Szeged, Hungary
ABSTRACT
Introduction: Parkinson’s disease is a neurodegenerative disorder which is characterized by the
combination of motor and non-motor symptoms. As yet, there is no curative treatment. The gold
standard for symptom control is levodopa. Two years after the start of substitution therapy, around 50%
of patients experience some degree of fluctuation in motor performance. Catechol-O-methyltransferase
(COMT) inhibitors are important agents in treating these fluctuations.
Areas covered: This article summarizes our knowledge about a new third-generation COMT inhibitor,
namely opicapone (OPC) (Search period: 2016–2019). The authors detail the pharmacological profile of
OPC and summarize the results of completed clinical trials. In addition, they briefly summarize the
achievements of the past few years.
Expert opinion: Based on clinical trials conducted so far, OPC is an effective and safe new drug. In
comparison to entacapone and tolcapone, it does not require close laboratory monitoring or multiple
oral administrations, which may result in better adherence. No serious adverse event was reported
during the drug development phases. Dyskinesia was the most common complaint. Further compara-
tive studies and broader trial inclusion criteria are needed to help the decision between COMT
inhibitors and to expand the patient spectrum where this drug can be applied.
ARTICLE HISTORY
Received 1 August 2019
Accepted 15 October 2019
KEYWORDS
COMT inhibitor; opicapone;
Parkinson’s disease
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder, which is
characterized by the combination of motor (bradykinesia, rest
tremor and rigidity) and non-motor symptoms (fatigue, anxiety,
leg pain, sleep disturbance, urinary problems, concentration diffi-
culties) [1,2]. The estimatedprevalence is around1–2per 1000, and
increases with age, 1% of the population is affected above the age
of 60 [3]. In Hungary there is a high prevalence (age-standardized
prevalence: 471/100,000) and incidence (age-standardized inci-
dence: 56/100,000/year) [4]. The main characteristic neuropatho-
logical feature of PD is the loss of dopaminergic neurons in the
substantia nigra (pars compacta) [5]. There is no curative treatment
according to our current knowledge. The gold standard of symp-
tomatic therapy is levodopa (L-dopa; LD) [6]. The most prominent
debilitating complication of long-lasting LD treatment is the devel-
opment of motor complications [7]. Two years after the start of
substitution therapy, around 50% of patients sense some degree
of fluctuation in motor performance [8]. The pathophysiological
background of fluctuations is the pulsatile and decreased dopami-
nergic stimulation of the striatal neurons [9].
Dopamine (DA) is not able to cross the blood-brain barrier
(BBB), therefore we use its precursor, LD. However, LD is rapidly
converted by DOPA decarboxylase (DDC) and catechol-
O-methyltransferase (COMT) enzymes to its metabolites in the
periphery (Figure 1; [10]). If we administer LD orally, only 1% will
penetrate into the central nervous system (CNS [11];). To increase
CNS availability of LD, we use DDC and COMT inhibitors. The
function of the COMT enzyme is to transfer a methyl group to
catecholamines. During the catalytic process S-adenosyl methio-
nine (SAM) is converted to S-adenosyl homocysteine (SAH) [10];
the detailed metabolism is presented in Figure 1. The most
common COMT inhibitors are entacapone (ENT) and tolcapone
(TLC) [12]. Since 24 June 2016 a third COMT inhibitor, namely
opicapone (OPC) is also available, which was approved by the
European Medicine Agency for the treatment of end-of-dose
motor fluctuations in adult patients whose symptoms are not
controllable by LD/DOPA decarboxylase inhibitor (DDCI) combi-
nation [13]. Probably the most important advantages of OPC in
comparison with second generation COMT inhibitors are the
following: there is a less frequent need to administer and there
is no real risk of hepatotoxicity [12].
The aim of this drug evaluation article is to summarize our
previous knowledge about the pharmacological profile and
clinical studies of OPC and to demonstrate the achievements
of the past few years.
1.1. Review data
The aim of this review article is to summarize our current knowl-
edge about on OPC. Relevant articles were collected through
the most important databases (PubMed (MEDLINE); Web of
Science; ScienceDirect; Wiley Online Library; Scopus). The search
period was from October 2016 to August 2019. (The article also
includes the most relevant data before October 2016. For more
information see our previous article [10].) The key terms of the
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search were ‘opicapone’ and ‘BIA 9-1067ʹ. We included the most
comprehensive reviews as further evaluation. The purpose of
this review article was primarily to summarize human results,
therefore preclinical articles were excluded. After collecting the
most relevant articles, we synthesized the most important data
and tried to provide an update on OPC.
1.2. Overview of the market
Currently two COMT inhibitors are in regular use: ENT and TLC
[7]. ENT is a safe product to be given several times a day [10].
Although TLC is more potent compared to ENT, TLC requires
close monitoring due to the potential risk of hepatotoxicity [13].
Nebicapone was another COMT inhibitor under development,
but had to be terminated due to the risk of hepatotoxicity [14].
Article highlights
● Since 24 June 2016 a third COMT inhibitor, namely opicapone (OPC) is
also available, which was approved by the European Medicine Agency
for the treatment of end-of-dose motor fluctuations in adult patients
whose symptoms are not controllable by LD/DOPA decarboxylase
inhibitor combination.
● OPC is a peripherally acting, reversible COMT inhibitor, requiring only
once daily administration compared to ENT, and has no documented
hepatotoxic effect as compared to TLC, thus no close laboratory
monitoring is required.
● The performed clinical trials did not register fatal outcome after OPC
treatment. The most common adverse event was dyskinesia.
● Further comparative studies and broader trial inclusion criteria are
needed to help the decision between COMT inhibitors and to expand
the patient spectrum where this drug can be applied.
Figure 1. The main steps of levodopa metabolism and important therapeutic targets and drugs. (3-MT – 3-methoxy-tyramine; 3-OMD – 3-O-methyldopa; AADC –
aromatic amino acid decarboxylase; BBB – blood-brain barrier; COMT – catechol-O-methyltransferase; DA – dopamine; DOPAC – 3,4-dihydroxy-phenylacetic acid;
ENT – entacapone; HVA – homovanillic acid; LD – levodopa; MAO – monoamine oxidase; OPC – opicapone; SAH – S-adenosyl homocysteine; SAM – S-adenosyl
methionine; SLCO1B1 – solute carrier organic anion transporter family, member 1B1; TCP – tolcapone).
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Currently OPC is in phase 4 trial (OPTIPARK, European Union) to
examine the safety and tolerability of a 50 mg OPC dose in
a selected PD population [7]. Currently OPC is marketed under
the Ongentys® brand name in the United Kingdom, Germany,
Spain, Italy and North America [7,10].
1.3. Introduction to the compound
OPC (BIA 9–1067; chemical name: 2,5-dichloro-3-(5-[3,4-dihy-
droxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyri-
dine-1-oxide) is a third-generation COMT inhibitor molecule
(Figure 1; Box 1) [15]. This drug is currently approved by the
European Medication Agency as an adjunctive therapy for the
treatment of those elderly PD patients, whose symptoms (end-
of-dose motor fluctuations) are not controllable with LD/DDCI
treatment. Ongentys® is the market name of OPC [15].
1.4. Chemistry
From a chemical perspective, OPC is a peripherally acting
compound, which has very high protein-binding affinity (in
the subpicomolar range) to the COMT enzyme [7,16]. The
pyridine N-oxide residue (position 3) is responsible for this
inhibitory potential and cell toxicity avoidance [17].
1.5. Pharmacodynamics
After oral administration, OPC shows a significant and long-
lasting COMT inhibitory effect [18–21]. The extent of inhibition
dependson the applieddose (5mg – 50%;≥ 200mg – 100%) [14].
Thanks to the slow complex dissociation rate OPC has a long-
lasting effect (24 h after the last dose (5–30 mg) – 50–70%)
[20,21]. If opicapone (25–100 mg) is given concomitantly with
immediate-/controlled-release 100/25 mg LD/carbidopa or with
immediate-/controlled-release 100/25 mg LD/benserazide drug,
LD and benserazide Cmax and AUC are elevated [22]. Previous
studies showed that ENT and TLC have shorter effect durations (8
and 18 h) [23,24]. Co-administration of OPC with another drug(s)
used in the treatment of PD (DA agonists, monoamine oxidase
B inhibitors) did not influence the pharmacological action
mechanism [25,26].
1.6. Pharmacokinetics and metabolism
Oral administration of OPC to healthy volunteers in different
doses (10 to 1200 mg) was performed by Almeida et al [18].
They found the terminal elimination half-life of OPC between 0.8
(50 mg) to 3.2 hours (1200 mg) [18]. The COMT inhibitory effect
seems to be dose-dependent [18]. The peak inhibitory effect was
36.1% by 10 mg OPC and 100% at doses greater than 200 mg
[18]. Interestingly, despite the relatively short half-life time, the
COMT inhibitory effect of OPC can be detected even after
24 hours, due to the slow dissociation rate [18]. Therefore,
a once-daily dosing regimen is sufficient [7,10].
As shown in Figure 1, there are many metabolites of
OPC, of which only BIA 9–1079 (reduced metabolite)
shows any metabolic activity [18,20]. The main elimination
route is sulfation via the hepato-biliary system (BIA 9–1103,
SULT1A1) [27]. In humans, BIA 9–1103 is the most important
metabolite. The effect of BIA 9–1103 on various transporters
was examined in vitro using CPMP/EWP/560/95/Rev. OPC is
transported by P-gp and BCRP and BIA 9–1103 is trans-
ported by OATP1B1 and -B3. There is evidence from
in vitro studies that OPC and BIA 9–1103 have inhibitory
effects on OAT1, −3, OATP1B1 and -B3, BSEP [28]. We know
from previous studies, that there is an increase in OPC levels
in patients with moderate liver impairment (Child-Pugh B)
[27]. Today there is no data about OPC pharmacokinetics in
severe liver dysfunction (Child-Pugh C),that is the reason,
why this drug is not recommended for this population [10].
A high-fat meal could delay the time of peak plasma drug
levels [29]. Sex, age and ethnicity do not influence the drug
effect [7]. Falcao et al. reported an RCT dose study (10 days:
OPC (5, 25, 50 mg) or PLC), which resulted in no significant
difference in pharmacokinetics and pharmacodynamics
between Caucasian and Japanese populations [30].
Regarding the relationship of LD availability and OPC, it
was demonstrated that OPC at 25, 50 and 75 mg signifi-
cantly increases the LD area under the curve (AUC) com-
pared to placebo (PLC) and ENT (in a latter case, 50 and
75 mg OPC) [19]. Rocha et al. administrated LD/carbidopa
(LC) or LD/benserazide (LB) in combination with OPC
according to two different study design protocols [31].
They showed that all applied doses of OPC (5, 15, 30 and
50 mg) resulted in higher extents of LD exposure
(AUC) [31].
OPC should be taken at bedtime once-daily after the last
administered LD/AADCI dose, to avoid any of possible pharma-
cokinetic interaction [32]. Clinical trials are investigating (cur-
rently no results are available) the pharmacokinetic effect of
OPC on repaglinide (NCT01536366), rasagiline (NCT01532141,
NCT01532128) and warfarin (NCT02169440, NCT02305030) [33].
Box 1. Drug summary box.
Drug name Opicapone
Phase IV
Indication Parkinson’s Disease
Pharmacology
description
Catechol-O-methyltransferase inhibitor (third
generation)
Route of
administration
Oral
Chemical structure
Pivotal trial(s) [21], BIPARK 1 and 2 [15,38] (NCT01568073;
NCT01227655)
Pharmaprojects – copyright to Citeline Drug Intelligence (an Informa
business). Readers are referred to Informa-Pipeline (http://informa-
pipeline.citeline.com) and Citeline (http://informa.citeline.com).
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1.7. Clinical efficacy
Two phase II and two phase III studies provide information on
clinical efficacy of OPC (Table 1) [17,21,34–36]. Thoroughly
selected PD patients were involved in the two randomized,
double-blind, controlled phase II studies (> 1.5 hours OFF time
daily; Hoehn and Yahr (HY) scale < 5; etc.) [21,34]. Rocha et al.
included 10 patients with PD in a study, in which they had an
improvement in ON time after a single oral OPC administra-
tion compared to placebo (18–25% ON-time increase
(25–50 mg OPC); 73% increase in ON-time without dyskinesia
(50 mg) [34]. Ferreira et al. also performed a randomized con-
trolled trial (RCT) with 35 PD patients (they used a similar
inclusion/exclusion criteria as Rocha et al), who received 28-
day long 5, 15 or 30 mg OPC [21]. All treatment regimens
resulted in a decrease in OFF time (5 mg – 15.6 min reduction
and 30 mg – 145 min reduction) and significant increase in ON
time without troublesome dyskinesia compared to PLC [21].
No serious adverse events were detected in the two studies
mentioned above [21,34].
The BIPARK-I study was a phase III study, in which 600
patients with PD were involved in a randomized, double-
blind, controlled way with the aim to estimate the clinical
efficacy of 5, 25 and 50 mg orally administrated OPC for
14–15 weeks compared to placebo or ENT [15]. The most
important criteria for patient selection were the following:
disease duration ≥ 3 years, stage 1–3 in HY scale and ≥
1.5 hours OFF time (excluding early morning akinesia) [15].
Furthermore, patients with a score greater than 3 on item 33
(disability) of the UPDRS and severe or unpredictable periods
in the off state were excluded as well [15]. The patients were
divided into five different groups: 5, 25 and 50 mg OPC (1 h
after the last LD dose, evening), PLC and 200 mg ENT [15]. The
major improvements were found in the 50 mg OPC group,
where OFF time reduction was significant in comparison to
PLC (−116.8 vs. −56 minutes) and this dose was non-inferior to
the ENT group as well (−116.8 vs. – 96.3 minutes) [15]. In the 5
and 25 mg groups there were no significant OFF time reduc-
tions [15]. In terms of ON time, in the 50 mg OPC group, there
was an increase in ON time without troublesome dyskinesia
compared to the PLC group [15]. From the perspective of non-
motor symptoms of PD, despite the seeming amelioration of
NMSS total score, no significant alteration was observed (The
39-Item Parkinson’s Disease Questionnaire (PDQ-39); Non-
motor Symptoms Scale (NMSS); Parkinson’s Disease Sleep
Scale (PDSS) [15]. Adverse reactions occurred in all five groups,
mostly dyskinesia [15]. Dyskinesia occurrence was most pro-
minent in the 50 mg OPC group [15]. No death was reported
during the study [15].
In the open label extension of the BIPARK-I study (495
patients were involved), the switch from PLC or ENT to OPC
resulted in a further decrease of OFF time (−65 min (PLC),
−39 min (ENT) and increase of ON time without dyskinesia
(43 min/PLC/, 45/ENT/) [35,36]. 25 mg was the applied OPC
dose in the first week, which was followed by an individual
response-dependent modification of dose [35,36]. 68.1% of
the patients reported mild to moderate adverse reactions.
Dyskinesia was the most common side effect, which was
more frequent in the 1–3 weeks. In summary, the OL extension
of the BIPARK-I study confirmed that the effect of opicapone
remained durable and safe for at least 1 year [37].
BIPARK-II was an RCT study, very similar to the BIPARK-I study,
with similar patient selection criteria [15,38]. The difference
between the two studies was the dose of OPC (in the BIPARK-II
study the 5 mg dose was omitted) and the number of patients
included (in this study it was lower, 427 PD patients) [17,38]. The
main result of this study was also similar to the BIPARK-I: 25 and
50 mg OPC reduced the OFF time in comparison with PLC group
(- 47 and – 54 minutes) [17,38]. Increase of ON time was also
detectable in OPC groups (1.4 h (25mg), 1.43 h (50 mg) and 0.8 h
(PLC) [38]. Similar to the above-mentioned clinical trial, no sig-
nificant alteration (but non-significant improvement in the NMSS
total score) was observed in non-motor scales (PDQ-39, NMSS,
PDSS, Unified Huntington’s Disease Rating Scale (UHDRS), global
assessment scale) [38]. No serious adverse event occurred during
the trial [38].
376 patients continued the treatment in the open label phase,
where the OFF time reduction seemed to be long-lasting and the
ON time increased by an additional 24.9 minutes [36].
Interestingly the overall analysis of BIPARK-I and -II trials
also examined the OFF time reduction effect above and below
2,5 HY stages and regarding disease duration time (more or
less than 8 years) [7,38]. The effect of 50 mg OPC on OFF time
reduction was independent of HY stage or disease dura-
tion [7,38].
Lees et al. analyzed the onset and the stabilization time of
the OPC over a 14–15 week study time period (BIPARK-I, -II).
They analyzed the data of 750 patients (PLC: 255; OPC (25 mg):
241; OPC (50 mg): 262). They found that there was an
improvement in the motoric performance already in the first
week of treatment (at week 1 mean OFF-time reduction was
23 min in the PLC group, in contrast, 61 min (OPC (25 mg) and
75 min (OPC (50 mg) in the treatment groups), which stabi-
lized after 2–3 weeks [39].
Currently, a phase IV clinical trial (NCT02847442, OPTIPARK)
is ongoing [7]. A 50 mg dose of OPC is applied orally over
a time period of 3–6 months with the involvement of 518 PD
patients [7].
1.8. Safety and tolerability
Several clinical trials assessed the safety (e.g. hepatotoxicity) or
tolerability problems regarding OPC [18–20]. In the conducted
phase I studies (single and repeated oral OPC doses) no
remarkable side effects occurred [18–20]. However, in light of
the fact that OPC is excreted via the hepatobiliary system,
there is a possibility of plasma concentration increase in hepa-
topathy [27]. That hypothesis led to test the pharmacological
profiles of OPC in patients with moderate liver disease which
showed a mildly elevated drug concentration level [27].
Therefore, dose reduction is an issue to consider in this popu-
lation [10]. From a cardiological perspective OPC does not
prolong the QTc value [40,41].
In the pooled analysis of two phase III trials (BIPARK-I and –
II) the following adverse events were revealed on the treated
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arms: dyskinesia, insomnia, dry mouth, dizziness, constipation,
blood creatine phosphokinase elevation [7,36]. In the open
label phases, no relevant new potentially treatment-related
adverse event occurred [7,36]. In the post-marketed period,
100 adverse events were reported (most frequently gastroin-
testinal- and psychiatric complaints) [42].
1.9. Regulatory affairs
As mentioned above, currently OPC is marketed in the United
Kingdom, Germany, Italy, Spain, North America (Bial-Portela &
Ca. S.A. has license agreement with Ono Pharmaceutical CO.,
Ltd., Neurocrine Biosciences, Inc. and with Jiangsu Wanbang
Biopharmaceutical Group Co., Ltd.).
2. Conclusion
OPC is a novel third-generation COMT inhibitor, which has
been shown to be an effective and safe drug based on clinical
trials conducted so far [15,18–21,34–36,38]. Compared to ENT,
the necessity of one daily dose may increase the adherence of
patients [15]. From previous studies we know that TLC
requires close laboratory monitoring for potential hepatotoxic
effect [7,10]. In contrast, OPC use did not result in detectable
liver function impairment [7].
This new peripherally acting, once daily drug, could be an
effective tool when treating PD with motor fluctuations. The
recommended dose is 50 mg daily orally, but the personalized
dose depends on the application of other antiparkinsonian
drugs. No dose modification is needed in mild liver impair-
ment (Child-Pugh B) or in renal failure [14,27].
The performed clinical trials did not register fatal outcome
after OPC treatment [7]. The most common adverse event was
dyskinesia [7,10,14].
3. Expert opinion
OPC is a novel third-generation, peripherally acting, reversible
COMT inhibitor, requiring only once daily administration com-
pared to ENT, and has no documented hepatotoxic effect as
compared to TLC, thus no close laboratory monitoring is
required. Accordingly, OPC may yield an add-on therapy with
improved efficacy to the gold standard medication, LD, in
advanced stages of PD. However, direct comparative trials
between COMT inhibitors are lacking. The BIPARK-I study
was the only trial, which reported the non-inferiority of OPC
to ENT [15]. Furthermore, the switch from ENT to OPC may
also be meaningful in relation to OFF time reduction [35].
From the perspective of non-motor symptoms there was
a non-significant improvement in the NMSS total score in
the BIPARK-I and II studies (with a sustained trend in the OL
phase) [7]. This effect was more evident in the 50 mg OPC
group [7]. Sleep and fatigue domains showed a positive
response to OPC [7]. Morning akinesia, OFF dystonia and
unpredictable end-of-dose fluctuations may also be important
treatment aspects, about which we have no direct information
from studies. Furthermore, trials are lacking regarding the
comparison of OPC with other possible add-on therapies
(e.g. rasagiline) in advanced stages of PD, so the decision
should be based on good clinical practice at the individual
level.
Nevertheless, OPC could serve as an effective therapeutic
tool in the treatment of ENT non-responder patients. Although
the data from studies are impressive, the global availability of
OPC may limit its world-wide application. Accordingly, the
increase of clinical experience and further studies are needed
to find the optimal place for this new drug in the treatment
of PD.
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